Your partner in advanced antibody development.

Originally a spin-out from Queen’s University Belfast, Fusion Antibodies began with a focus on mouse hybridoma technology and quickly evolved to develop our proprietary CDRx® humanization platform, which has since become a cornerstone of our services.

Over the years, we have significantly expanded our capabilities and now offer:

• Five antibody discovery engines, including animal immunization using mouse and rabbit models, our proprietary OptiMAL® library of fully human full length antibodies using Mammalian Display, the AI-powered AI/ML-ab™ discovery platform, which can also be combined with Mammalian Display, and the proprietary OptiPhage™ phage display platform.
• Advanced engineering services such as humanization, developability optimization, Fc engineering, reformatting, and our proprietary Rational Affinity Maturation Platform (RAMP™).
• Comprehensive antibody characterization and assay development.
• Small to large scale antibody production by mammalian cell transient expression, and stable cell line development services.

Fusion Antibodies has completed over 1,750 successful antibody development projects globally, with 12 therapeutic antibodies advanced to clinic. We’ve partnered with over 700 organizations globally, including top pharmaceutical companies and leading academic institutions.

Recent Development Highlights include:

• Ongoing collaboration with the U.S. National Cancer Institute, leveraging our OptiMAL® platform to develop next-generation cancer therapeutics.
• ISO 9001:2015 accreditation, ensuring the highest standards of quality and reliability across all our services.
• Newly developed platforms tailored for veterinary antibody discovery, supporting innovation across companion animal and livestock health.

Values that Fusion Antibodies bring to the clients:

• Fusion has a strong track record of delivering antibodies that are not only highly functional but also optimized for manufacturability.
• Clients appreciate Fusion’s collaborative approach and the ability to tailor services to meet specific project needs, effectively acting as an extension of their internal R&D teams.
• Our transparent pricing model and clear communication on project progress are consistently valued by clients.
• Clients resonate with Fusion’s mantra “begin with the end in mind”, recognizing our proactive mindset in designing solutions that align with the intended final application.
• Fusion’s commitment to protecting client intellectual property, supported by robust UK regulatory standards, is seen as a key differentiator, especially in contrast to jurisdictions with export controls or IP acquisition concerns.

Connect with our specialists to explore tailored solutions for your project.

Five discovery engines, advanced engineering services and scalable expression help programmes move from the right biological question to a development-ready candidate.

• Integrated discovery and screening
• Humanization, developability and Fc engineering
• Transient expression and stable cell line development

We act as an extension of internal R&D teams, communicating clearly, protecting client IP and keeping every experiment linked to the next meaningful decision.

• Ongoing collaboration with the U.S. National Cancer Institute, leveraging OptiMAL® to develop next-generation cancer therapeutics.
• ISO 9001:2015 accreditation supports consistent, reliable delivery.
• New platforms tailored for veterinary antibody discovery support companion animal and livestock health.

• Functional antibodies optimised for manufacturability.
• A collaborative approach that acts as an extension of internal R&D teams.
• Transparent pricing and clear communication on project progress.
• “Begin with the end in mind” decision-making aligned to the final application.
• Robust UK standards and protection of client intellectual property.

Explore tailored solutions for your project with the people who understand the science and the decision that comes next.